GlassScriptPhysician profile
Bixuan Lin
NPI 1992236707
$8,650.46
in general payments reported to CMS, 2019-2025
23 companies · $4,132 in 2025
The $4,132 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2022: $112 · 2023: $548 · 2024: $3,737 · 2025: $4,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,380 · Travel and Lodging: $1,995 · Education: $41.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,380.25 |
| Travel and Lodging | $1,994.75 |
| Education | $41.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,094.67 | 2023-2025 | |
| Genentech, INC. | $1,677.38 | 2025 | |
| Genentech USA, INC. | $1,278.78 | 2024 | |
| Medtronic, INC. | $597.60 | 2023-2025 | Manoscan, Nexpowder, Endoflip |
| Janssen Scientific Affairs, LLC | $555.99 | 2024-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $395.18 | 2023-2024 | Vemlidy, Epclusa |
| Janssen Biotech, INC. | $349.49 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $290.10 | 2024-2025 | Spyglass, Apollo 2-0 Polypropylene Endobariatric Suture, Orise |
| Lilly USA, LLC | $219.46 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $194.93 | 2020-2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $186.37 | 2024-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $176.78 | 2024-2025 | Rebyota |
| Madrigal Pharmaceuticals | $126.46 | 2025 | Rezdiffra |
| Steris Corporation | $117.91 | 2024 | |
| Intercept Pharmaceuticals, INC. | $111.99 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $106.01 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $46.77 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $35.97 | 2024 | Dupixent |
| Pfizer INC. | $34.48 | 2024-2025 | |
| Vibrant Gastro, INC. | $22.00 | 2025 | Vibrant Starter Kit |
| Genzyme Corporation | $21.99 | 2024 | |
| Phathom Pharmaceuticals, INC. | $10.15 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bixuan Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.